Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis and US Close to Reaching Deal in Bribery Case

Confidential settlement talks between Novartis AG and the U.S. government over allegations that the company paid doctors to market its products are not so secret anymore. The U.S. sued the Swiss dr...

Clinical Trials Confirmed Cosentyx Status as Comprehensive Treatment of Psoriatic Arthritis

Novartis, a leader in rheumatology and immuno-dermatology, announced new data from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestat...

Sanofi Appointed New CEO

At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire. ...

Novartis Appointed New President of Pharmaceuticals Business Unit

novartis
Novartis announced that Marie-France Tschudin, currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed President, Novartis Pharmaceuticals. She will report...

EMA Committee Recommended Marketing Authorization for Novartis’ LysaKare

european medicines agency
Advanced Accelerator Applications S.A. (AAA), a Novartis company, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opin...

Novartis Announced Results from the Landmark COMBI-d and COMBI-v Clinical Trials

novartis
Novartis announced results from the landmark COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) offers both overall and prog...

Novartis and Sumitomo Signed Collaboration Agreement for Diabetes Treatments in Japan

Sumitomo Dainippon Pharma Co., Ltd. signed a co-promotion and sales collaboration agreement with Novartis Pharma K.K. for Equa® 50mg tablets (generic name: vildagliptin; hereinafter “Equa”), a selecti...

Novartis to Pay Sosei $2.5m for QVM149 Marketing Authorization Application

The European Medicines Agency (EMA) has accepted Sosei Heptares’ filing for QVM149, a potential new inhaled combination therapy for asthma. Novartis is responsible for the development and commercia...

FDA Approved Incyte’s treatment for Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp’s treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplan...

GSK and Novartis Promote False Claims about Products Efficacy

The Federal Court of Australia has found that the subsidiaries of pharmaceutical companies GlaxoSmithKline (GSK) and Swiss drug manufacturer Novartis breached Australian Consumer Law by promoting fals...

Novartis’ Piqray Granted Approval by FDA

The U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with h...

Novartis Pipeline Has More than 25 Blockbusters

novartis
Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline. CEO Vas Narasimhan reitera...

Eisai Announced Ex-Novartis Dezzani as U.S. Medical Affairs’ Vice President

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group. He will be ...

Novartis’ Cancer Treatment Kymriah Approved for Sale in Japan

A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-sta...

Novartis Recalls Promacta because of Possible Penut Contamination

novartis
Novartis has begun a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potent...

Novartis Agreed to Pay $3.4 billion for Eye Drug Assets

Novartis AG agreed to pay $3.4 billion for eye-disease medicines that Takeda Pharmaceutical Co. is selling to shed debt after its $62 billion acquisition of Shire Plc. The main product in the deal ...